CardioDx, Inc. Blood-Based Gene Expression Test Demonstrates Superior Performance to Myocardial Perfusion Imaging to Rule Out Obstructive Coronary Artery Disease

Published: Nov 16, 2011

PALO ALTO, Calif.--(BUSINESS WIRE)--CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, announced results of its COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) trial, which were presented today at the American Heart Association Scientific Sessions 2011 conference in Orlando, Fla. This prospective, blinded multi-center study was designed to provide a third independent validation of the CorusĀ® CAD blood-based gene expression test for ruling out obstructive coronary artery disease in lower-risk patients with typical and atypical presentations of stable chest pain, and to compare the diagnostic performance of Corus CAD to myocardial perfusion imaging (MPI), a common test that uses a radioactive agent to evaluate the blood flow and function of the heart.

Back to news